Provention Bio Financials

Based on the analysis of Provention Bio's profitability, liquidity, and operating efficiency, Provention Bio is not in a good financial situation at the moment. It has a very high risk of going through financial straits in January.
  
Please note, the presentation of Provention Bio's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Provention Bio's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Provention Bio's management manipulating its earnings.

Provention Bio Stock Summary

Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Provention Bio, Inc. was incorporated in 2016 and is headquartered in Red Bank, New Jersey. Provention Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 82 people.
InstrumentUSA Stock View All
ExchangeNASDAQ Exchange
ISINUS74374N1028
Business Address55 Broad Street,
SectorPharmaceuticals
IndustryHealth Care
BenchmarkDow Jones Industrial
Websitewww.proventionbio.com
Phone908 336 0360
CurrencyUSD - US Dollar

Provention Bio Key Financial Ratios

Provention Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Provention Bio's current stock value. Our valuation model uses many indicators to compare Provention Bio value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Provention Bio competition to find correlations between indicators driving Provention Bio's intrinsic value. More Info.
Provention Bio is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Provention Bio's earnings, one of the primary drivers of an investment's value.
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.
You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.

Other Consideration for investing in Provention Stock

If you are still planning to invest in Provention Bio check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Provention Bio's history and understand the potential risks before investing.
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Money Managers
Screen money managers from public funds and ETFs managed around the world
Global Correlations
Find global opportunities by holding instruments from different markets